1‐Deoxynojirimycin attenuates pathological markers of Alzheimer's disease in the in vitro model of neuronal insulin resistance
Open Access
- 9 July 2024
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 38 (13) , e23800
Abstract
Insulin resistance, the hallmark of type 2 diabetes mellitus (T2DM), has emerged as a pathological feature in Alzheimer's disease (AD). Given the shared role of insulin resistance in T2DM and AD, repurposing peripheral insulin sensitizers is a promising strategy to preserve neuronal insulin sensitivity and prevent AD. 1‐Deoxynojirimycin (DNJ), a bioactive iminosugar, exhibited insulin‐sensitizing effects in metabolic tissues and was detected in brain tissue post‐oral intake. However, its impact on brain and neuronal insulin signaling has not been described. Here, we investigated the effect of DNJ treatment on insulin signaling and AD markers in insulin‐resistant human SK‐N‐SH neuroblastoma, a cellular model of neuronal insulin resistance. Our findings show that DNJ increased the expression of insulin signaling genes and the phosphorylation status of key molecules implicated in insulin resistance (Y1146‐pIRβ, S473‐pAKT, S9‐GSK3B) while also elevating the expression of glucose transporters Glut3 and Glut4 , resulting in higher glucose uptake upon insulin stimuli. DNJ appeared to mitigate the insulin resistance‐driven increase in phosphorylated tau and Aβ 1‐42 levels by promoting insulin‐induced phosphorylation of GSK3B (a major tau kinase) and enhancing mRNA expression of the insulin‐degrading enzyme (IDE) pivotal for insulin and Aβ clearance. Overall, our study unveils probable mechanisms underlying the potential benefits of DNJ for AD, wherein DNJ attenuates tau and amyloid pathologies by reversing neuronal insulin resistance. This provides a scientific basis for expanding the use of DNJ‐containing products for neuroprotective purposes and prompts further research into compounds with similar mechanisms of action.Keywords
Funding Information
- Japan Society for the Promotion of Science (21J12380)
This publication has 46 references indexed in Scilit:
- Effect of 1-Deoxynojirimycin on insulin resistance in prediabetic mice based on next-generation sequencing and intestinal microbiota studyJournal of Ethnopharmacology, 2022
- Brain Insulin Signaling, Alzheimer Disease Pathology, and Cognitive FunctionAnnals of Neurology, 2020
- 1-Deoxynojirimycin modulates glucose homeostasis by regulating the combination of IR-GlUT4 and ADIPO-GLUT4 pathways in 3T3-L1 adipocytesMolecular Biology Reports, 2019
- Neuroprotective effect of 1-Deoxynojirimycin on cognitive impairment, β-amyloid deposition, and neuroinflammation in the SAMP8 miceBiomedicine & Pharmacotherapy, 2018
- Chronic adjunction of 1-deoxynojirimycin protects from age-related behavioral and biochemical changes in the SAMP8 miceAGE, 2015
- Production of the α-glycosidase inhibitor 1-deoxynojirimycin from Bacillus speciesFood Chemistry, 2013
- Determination of iminosugars in mulberry leaves and silkworms using hydrophilic interaction chromatography–tandem mass spectrometryAnalytical Biochemistry, 2010
- Insulin-stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependentBrain Research, 2009
- Insulin regulates neuronal glucose uptake by promoting translocation of glucose transporter GLUT3Experimental Neurology, 2006
- Brain glucose metabolism in the early and specific diagnosis of Alzheimer?s diseaseEuropean Journal of Nuclear Medicine and Molecular Imaging, 2005